Nocardiosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
A new combination drug therapy ([[sulfonamide]], [[ceftriaxone]], and [[amikacin]]) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis. | A new combination drug therapy ([[sulfonamide]], [[ceftriaxone]], and [[amikacin]]) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis. | ||
Revision as of 19:45, 10 December 2012
|
Nocardiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Nocardiosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Nocardiosis future or investigational therapies |
|
Risk calculators and risk factors for Nocardiosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis.